Volgens onderstaand bericht gaan
Ian Lipkin en
in het kader van het Chronic Fatigue Initiative
met nieuwe techieken (deep sequencing)
op zoek naar
biomarkers, pathogenen (ziekteverwekkers) en ziektemechanismen.
In het kader van de geopperde onvooringenomenheid het wel merkwaardig
dat de onderzoekers min of meer veronderstellen dat de pathogeen niet uitmaakt en
dat ze de ziekte als neuropsychiatrisch kwalificeren, en niet als neuro-immunologisch.
We zullen zien...
Dr. Ian Lipkin and Dr. Mady Hornig, use deep sequencing and proteomics to hunt CFS viruses
November 4, 2011
In the end, cutting edge technology may be the game-changer in chronic fatigue syndrome –
a condition that strikes an estimated 1-4 million patients in the United States.
Viral involvement and immune system abnormalities
have long been suspected as contributing or causing the disease.
But for many reasons, including the multiple definitions used,
delays in diagnosis and small sample size, study results have been mixed.
Unlike microarray chips that have a finite number of known pathogens for testing,
deep sequencing allows researchers to find not only an unlimited number of varying strains of known pathogens,
but novel pathogens as well.
Testing will most likely be done at a sequencing center pooling the resources of several large centers
as the equipment is very expensive and personnel have to be specially trained, according to Dr. Hornig.
"We show quite clearly
a wide range of infectious agents can trigger similar pathways in immune system
that result in similar outcomes
so it may well be that there are many patho-gens who have capacity to cause chronic fatigue syndrome
by either inducing autoimmunity or some sort of impact on the immune function which results in activation," said Lipkin,
who plans to examine other hypotheses as well depending on the results of initial tests.
"The effort in ME/CFS to try to find some biomarkers
that will be likely to identify a set of pathways that are likely to involved.
That will be an enormous gain for the field and of course the patient," said Dr. Hornig.
Biomarkers in ME/CFS can be used to create diagnostic laboratory tests
as well as to determine therapy response and prognosis.
The key to maximizing the outcomes of these tests
is the criteria of the patients selected, according to Dr. Lipkin.
He said this will give the greatest possibility of finding objective measures for monitoring and measuring the disease.
University of Miami researcher and physician Dr. Nancy Klimas,
who has been involved in several clinical definitions of ME/CFS,
is in charge of the cohort requirement
to draw 200 patients from five sites located throughout the U.S.
Both Dr. Lipkin, who is a board certified neurologist,
and Dr. Hornig, who is a board certified psychiatrist, stress that
while they believe ME/CFS is a neuropsychiatric disorder
because of the problems with concentration, memory and autonomic nervous system involvement,
they do not consider it psychosomatic.
Met dank aan Rob.